Lafutidine, a new gastric ulcer drug of Changjiang Pharmaceutical Co., Ltd

According to the information on the website of the State Food and Drug Administration (CFDA) on August 6, the raw materials and tablets of lafutidine, a class 3.1 chemical drug of Yichang Changjiang Pharmaceutical Co., Ltd., a joint stock company of dongyangke, will enter the site for inspection this month Lafutidine is mainly used in the treatment of gastric ulcer, duodenal ulcer and anastomotic ulcer It is the second generation histamine H2 receptor antagonist jointly developed by Fuji company and Dapeng company in Japan Compared with the first generation products cimetidine, ranitidine and famotidine, lafutidine has the advantages of high efficacy, slight side effects and low treatment cost At present, five domestic pharmaceutical companies have been approved to produce lafutidine tablets, including Kelun pharmaceutical and Cr Shuanghe Dongyangke is a large-scale professional hydrophilic foil manufacturer In recent years, the company has increased R & D investment in pharmaceutical business According to the statistics of big wisdom news agency, Guangdong dongyangguang Pharmaceutical Co., Ltd., another joint-stock subsidiary of dongyangke, has successively applied for more than 10 drugs to CFDA this year The treatment fields include respiratory tract infection, irritant dry cough, type 2 diabetes, primary Parkinson's disease, high cholesterol, tumor, influenza, unstable angina, schizophrenia, etc.